2-azidododecanoic acid | 717132-35-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-azidododecanoic acid
• 英文别名: 2-Azido-dodecansaeure；Azido-dodecanoic acid
• CAS: 717132-35-9
• 化学式: C₁₂H₂₃N₃O₂
• 分子量: 241.334
• InChiKey: RHLOBEWNFURTOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  17
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  51.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-azidododecanoic acid 在 吡啶 、 氯化亚砜 、 氯仿 作用下， 生成 2-(2-azido-dodecanoyloxy)-1,3-bis-stearoyloxy-propane
  参考文献：
  名称：

  Mono-α-aminoacyl and Mono-α-dipeptide Triglycerides

  摘要：

  DOI：

  10.1021/ja01606a036
• 作为产物：
  描述：

  2-溴月桂酸 在 sodium azide 作用下， 以 水 、 丙酮 为溶剂， 反应 1.0h， 生成 2-azidododecanoic acid
  参考文献：
  名称：

  新的曲霉毒素，脂肽天然产物，通过构巢曲霉中的HDAC抑制得到揭示

  摘要：

  释放真菌的生化储藏是开发未来药物的关键。通过减少关键的组蛋白脱乙酰基酶在构巢曲霉中的表达，在15种新的Aspercryptins（最近描述的脂肽，具有两个衍生自辛酸和十二烷酸的非规范性氨基酸）的水平中，观察到最多100倍的增加。除了两个经过NMR验证的结构外，MS / MS网络还帮助发现了另外13种aspercryptins。与这类已知化合物相比，曲霉毒素破坏了脂肽的常规结构取向，并显示为“向后”。我们还证实了14个基因的Aspercryptin生物合成基因簇，该簇编码两个脂肪酸合酶和几种酶，可以将饱和的辛酸和十二烷酸转化为α-氨基酸。

  DOI：

  10.1021/acschembio.6b00398

文献信息

• [EN] THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING<br/>[FR] CONJUGUÉS THÉRAPEUTIQUES COMPORTANT DES DENDRIMÈRES SULFATÉS POUR CIBLAGE INTRACELLULAIRE
  申请人：IC DISCOVERY GMBH

  公开号：WO2015177279A1

  公开（公告）日：2015-11-26

  The present invention relates to novel dendrimer conjugates, methods for their preparation and their use for treatment of diseases. The invention discloses a new method for the delivery of dendrimer conjugates with therapeutically active molecules into the cell by utilizing transmembrane solute carrier proteins enabling uptake of the inventive dendrimer conjugates. Particular subject-matter of the present invention is a conjugate of the formula E-[G-L- D(OSO3-M+)n]m,wherein E is a therapeutic or diagnostic effector molecule, wherein D(OSO3-M+)n is a dendrimer D carrying a number n of sulfate groups OSO3-M+, wherein the number n of sulfate groups is selected from 6 to 96, wherein M is a cationic inorganic or organic counter ion to the anionic sulfate group, wherein L is a linker or spacer between D and E, wherein G is a connecting functional group forming the attachment between L and E, and wherein m is an integer from 1 to 20.

  本发明涉及新型树状分子共轭物、其制备方法以及用于治疗疾病的方法。该发明揭示了一种新的方法，通过利用跨膜溶质载体蛋白，使创新的树状分子共轭物能够进入细胞，从而传递治疗活性分子。本发明的特定主题是公式E-[G-L-D（OSO3-M+）n]m的共轭物，其中E是治疗或诊断效应分子，D（OSO3-M+）n是携带n个硫酸酯基团OSO3-M+的树状分子D，硫酸酯基团的数量n选自6到96，其中M是阳离子无机或有机对阴离子硫酸酯基团的反离子，L是D和E之间的连接剂或间隔物，G是连接L和E的连接功能基团，m是1到20的整数。
• Encapsulated diagnostics and therapeutics in nanoparticles—conjugated to tropic cells and methods for their use
  申请人：CITY OF HOPE

  公开号：US10426801B2

  公开（公告）日：2019-10-01

  A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

  提供了一种治疗或诊断递送载体。递送载体可包括一种或多种颗粒，如微颗粒、纳米颗粒和刺激响应颗粒，这些颗粒与滋养细胞连接，针对至少一个病理实体或部位。此外，还提供了一种药物组合物。除其他外，药物组合物可包括与滋养细胞（如上文讨论的那些）共轭的颗粒和至少一种诊断或治疗剂（如本文描述的那些）。在某些方面，滋养细胞可针对至少一种病理实体或部位。此外，还提供了诊断、监测或治疗受试者病理状况的方法。此类方法可包括向受试者施用治疗有效量的药物组合物。
• THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING
  申请人：IC Discovery GmbH

  公开号：EP3145984A1

  公开（公告）日：2017-03-29
• ENCAPSULATED DIAGNOSTICS AND THERAPEUTICS IN NANOPARTICLES - CONJUGATED TO TROPIC CELLS AND METHODS FOR THEIR USE
  申请人：CITY OF HOPE

  公开号：US20150056144A1

  公开（公告）日：2015-02-26

  A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.